Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01375491 · ClinicalTrials.gov registry record · Phase 4
Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans
A Phase 4 study of Obesity and Type 2 Diabetes, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 4
- Development phase
- 39
- Enrollment target
- 1
- Study location
NCT01375491: Completed Phase 4 study of Obesity and Type 2 Diabetes, sponsored by University of California, San Diego.
NCT01375491 is a Phase 4 study of Obesity and Type 2 Diabetes that has completed, run by University of California, San Diego. The registered enrollment target is 39 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01375491, a Phase 4 study of Obesity and Type 2 Diabetes, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 39 participants
- Enrollment target
- 1
- Study location
Study Summary
Obesity is a heightened state of inflammation in which production of cytokines and matrix metalloproteinases (MMPs) result in loss of function of insulin receptors and insulin resistance. Doxycycline (DOX) is a potent MMP inhibitor. We hypothesize that DOX will enhance insulin sensitivity and decreases inflammation in obese participants with type 2 diabetes (DM2).
Primary Outcome
MMP activity is measured using a charge-changing peptide substrate for MMP-2 and MMP-9.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Doxycycline
Study Locations (1)
California
- University of California San Diego Clinical trials Research Institute - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2009-10 |
| Est. Completion | 2011-06 |
| Phase | Phase 4 |
What the finished NCT01375491 record still lists
NCT01375491 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01375491 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01375491 about?
NCT01375491 is a clinical study titled "Examination of the Anti-inflammatory and Insulin Sensitizing Properties of Doxycycline in Humans". Obesity is a heightened state of inflammation in which production of cytokines and matrix metalloproteinases (MMPs) result in loss of function of insulin receptors and insulin resistance. Doxycycline (DOX) is a potent MMP inhibitor. We hypothesize that DOX will enhance insulin sensitivity and decrea...
What is the current status of trial NCT01375491?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 39 participants. The study started on 2009-10. Estimated completion is 2011-06.
What conditions does trial NCT01375491 study?
This clinical trial studies the following conditions: Obesity, Type 2 Diabetes.
What interventions are being tested in trial NCT01375491?
The interventions under investigation include: Placebo (OTHER), Doxycycline (DRUG).
Who is sponsoring clinical trial NCT01375491?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01375491 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01375491's enrollment target sits among peer trials
39 806th of 1053 higher than 244 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
RECRUITING · Phase 4
-
Phenotype-Tailored Lifestyle Intervention for Obesity: A Randomized Trial
RECRUITING · Phase 4
-
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
RECRUITING · Phase 4
-
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
RECRUITING · Phase 4
-
Fibrosis Lessens After Metabolic Surgery
RECRUITING · Phase 4
-
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia